Display options
Share it on
Full text links
Springer

Eur J Clin Pharmacol. 1993;45(3):221-5. doi: 10.1007/BF00315387.

Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

European journal of clinical pharmacology

S Güldütuna, M Leuschner, N Wunderlich, A Nickel, S Bhatti, K Hübner, U Leuschner

Affiliations

  1. Department of Gastroenterology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.

PMID: 8276045 DOI: 10.1007/BF00315387

Abstract

We treated 6 patients with Stage II primary biliary cirrhosis with cholic acid (CA) 10 mg.kg-1 per day for 3 months and then with the same dose of ursodeoxycholic acid (UDCA). A matching group of 6 patients was observed for 3 months without any therapy. Liver function tests and serum and stool bile acids were investigated before, during and at the end of CA and UDCA therapy. The results of liver function tests deteriorated after 6-8 weeks of CA therapy and the changes were correlated (r = 0.92) with an increase in alpha-dihydroxy-bile acids (chenodeoxycholic acid and deoxycholic acid) in the serum. The 24 h excretion of DCA in 24 h faeces was markedly increased. Ursodeoxycholic acid treatment improved liver function tests; after 4 weeks glutamate dehydrogenase (GLDH) had decreased. After 8-12 weeks of therapy ursodeoxycholic acid had increased to 50-60% of the total serum bile acids whereas the more apolar bile acids were significantly decreased. No changes in liver function tests or bile acid metabolism were found in the untreated group. Since CA and UDCA are non-toxic in man, this trial indicates that the apolar bile acids chenodeoxycholic acid and deoxycholic acid may be responsible for the deterioration of liver function in primary biliary cirrhosis. However, the therapeutic effect of UDCA cannot be explained merely by the decrease in alpha-dihydroxy-bile acids in the serum, since the laboratory results had improved prior to the decrease in the serum apolar bile acids.

References

  1. Life Sci. 1982 Feb 7;30(6):515-23 - PubMed
  2. Prog Liver Dis. 1970;3:336-54 - PubMed
  3. Gastroenterology. 1993 Jun;104(6):1736-44 - PubMed
  4. Gastroenterology. 1988 May;94(5 Pt 1):1201-6 - PubMed
  5. Hepatology. 1991 Nov;14(5):920-6 - PubMed
  6. Dig Dis Sci. 1979 Feb;24(2):123-8 - PubMed
  7. Gastroenterology. 1990 Feb;98(2):424-8 - PubMed
  8. Hepatology. 1990 Sep;12(3 Pt 1):486-91 - PubMed
  9. J Hepatol. 1990 May;10(3):284-90 - PubMed
  10. Gastroenterology. 1972 Jun;62(6):1174-81 - PubMed
  11. Gastroenterology. 1983 Dec;85(6):1248-56 - PubMed
  12. Hepatology. 1989 Oct;10(4):414-9 - PubMed
  13. Dig Dis Sci. 1982 Aug;27(8):737-61 - PubMed
  14. Gastroenterology. 1975 Feb;68(2):326-34 - PubMed
  15. Gastroenterology. 1989 Nov;97(5):1268-74 - PubMed
  16. Nihon Shokakibyo Gakkai Zasshi. 1975 Jun;72(6):690-702 - PubMed
  17. Am J Gastroenterol. 1990 Jan;85(1):15-23 - PubMed
  18. Gastroenterology. 1976 Aug;71(2):196-201 - PubMed
  19. Dig Dis Sci. 1989 Dec;34(12 Suppl):5S-15S - PubMed
  20. Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):423-30 - PubMed
  21. Eur J Clin Invest. 1977 Oct;7(5):383-8 - PubMed
  22. J Lipid Res. 1980 Jan;21(1):23-34 - PubMed
  23. Gastroenterology. 1980 Jun;78(6):1402-11 - PubMed
  24. N Engl J Med. 1972 Jan 6;286(1):1-8 - PubMed
  25. Gastroenterology. 1974 Oct;67(4):674-9 - PubMed
  26. Gastroenterology. 1975 Dec;69(6):1301-14 - PubMed
  27. Gut. 1991 Sep;32(9):1044-8 - PubMed
  28. Hepatology. 1990 Sep;12(3 Pt 1):492-7 - PubMed
  29. Clin Chim Acta. 1993 Feb 28;214(2):195-207 - PubMed
  30. Gastroenterology. 1991 Jan;100(1):203-11 - PubMed
  31. Hepatology. 1991 Dec;14(6):1000-7 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources